EC Cardiology

Review Article Volume 10 Issue 4 - 2023

RNA Vaccines and Prevalence of Heart Disorders

ND Victor Carsrud1†, Nicholas A Kerna2,3†*, Hilary M Holets4, Sudeep Chawla5, John V Flores4, Dabeluchi C Ngwu6,7, Kevin D Pruitt8,9 , Chizoba M Ani10 and Cornelius I Azi11

1Lakeline Wellness Center, USA
2Independent Global Medical Research Consortium
3First InterHealth Group, Thailand
4Orange Partners Surgicenter, USA
5Chawla Health & Research, USA
6Cardiovascular and Thoracic Surgery Unit, Department of Surgery, Federal Medical Center, Umuahia, Nigeria
7Earthwide Surgical Missions, Nigeria
8Kemet Medical Consultants, USA
9PBJ Medical Associates, LLC, USA
10James Lind Institute, Switzerland
11Northern Care Alliance NHS Foundation Trust, UK

*Corresponding Author: Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500. Contact: † indicates co-first author
Received: March 15, 2023; Published: March 25, 2023

RNA vaccines are appealing because they share traits with live-attenuated vectors and subunit vaccines, such as flexible manufacturing and generating humoral and cellular resistance. In recent years, vaccine production employing ribonucleic acid (RNA) has emerged as the most promising and explored strategy for producing safe and effective novel vaccines, not just for prevention but also as a therapy. Compared to conventional vaccines, using messenger RNA (mRNA) as an immunogen offers various benefits in vaccine production, including a cheaper cost, the absence of cell cultures, and the ability to mix diverse targets.

Most significantly, mRNA-based vaccines have the potential to bridge the gap between growing pandemic infectious illnesses and an ample supply of effective vaccinations. Despite its advantages for vaccine application, mRNA technology confronts numerous critical hurdles, including worries about mRNA enzyme degradation, permeability, vaccine stability or inflammation, autoimmune problems, and cardiovascular problems. A recent report by the Centers for Disease Control and Prevention (CDC) advisory group on vaccination policies found that there is probably a link between cardiovascular (CV) diseases and the COVID-19 mRNA vaccine. According to research from the United States, the United Kingdom, and Switzerland, myocarditis and pericarditis are the most common cardiovascular complications in teenage boys following COVID-19 mRNA vaccination. Treatment of vaccine-induced CV disorders includes corticosteroids, NSAIDs, colchicine, and, in severe cases, IVIG. Corticosteroids and percutaneous coronary intervention (PCI) with guideline-directed medical therapy (GDMT) have also been proposed to treat vaccine-induced myocarditis. Complementary and alternative medicine (CAM) may assist patients with CV disease, but physicians and patients may overlook its use.

This study aims to review the history, investigate, summarize, and simplify the understanding of the association between RNA vaccines and heart disorders.

Keywords: Autoimmune Disorders; Complementary and Alternative Medicine; Enzyme Degradation; Vaccine-Induced Disorders

  1. Jain S., et al. “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic”. Advanced Drug Delivery Reviews 179 (2021): 114000.
  2. Wadhwa A., et al. “Opportunities and challenges in the delivery of mRNA-based vaccines”. Pharmaceutics2 (2020): 102.
  3. “RNA vaccines: a novel technology to prevent and treat disease”. Science in the News (2022).
  4. Pardi N., et al. “mRNA vaccines-a new era in vaccinology”. Nature Reviews Drug Discovery4 (2018): 261-279.
  5. RNA vaccines: an introduction. PHG Foundation (2022).
  6. Lakhotia SC. “Central dogma, selfish DNA and noncoding RNAs: A historical perspective”. Proceedings of the Indian National Science Academy 97 (2018).
  7. Ebertz A. “The history of mRNA applications”. The DNA Universe BLOG (2022).
  8. Dolgin E. “The tangled history of mRNA vaccines”. Nature7876 (2021): 318-324.
  9. Schlake T., et al. “Developing mRNA-vaccine technologies”. RNA Biology11 (2012): 1319-1330.
  10. Jirikowski GF., et al. “Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA”. Science5047 (1992): 996-998.
  11. Sahin U., et al. “mRNA-based therapeutics-developing a new class of drugs”. Nature Reviews Drug Discovery10 (2014): 759-780.
  12. Government of Canada, Canadian Institutes of Health Research. The long road to mRNA vaccines (2022).
  13. Machado BAS., et al. “The importance of RNA-based vaccines in the fight against COVID-19: An overview”. Vaccines11 (2021): 1345.
  14. Lin CJ., et al. “RNA vaccines for COVID-19: 5 things every cardiologist should know”. JACC: Basic to Translational Science12 (2020): 1240-1243.
  15. Trougakos IP., et al. “Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis”. Trends in Molecular Medicine's7 (2022): 542-554.
  16. Habib MB., et al. “Acute myocarditis following administration of BNT162b2 vaccine”. ID Cases 25 (2021): e01197.
  17. Duthie MS., et al. “Leishmaniasis vaccines: Applications of RNA technology and targeted clinical trial designs”. Pathogens11 (2022): 1259.
  18. World Health Organization. Evaluation of the Quality, Safety and Efficacy of RNA-Based Prophylactic Vaccines for Infectious Diseases: Regulatory Considerations (2020): 1.
  19. Coveney S. “What is an RNA vaccine? News-medical (2022).
  20. Qin S., et al. “mRNA-based therapeutics: powerful and versatile tools to combat diseases”. Signal Transduction and Targeted Therapy1 (2032): 166.
  21. What’s different about messenger RNA (mRNA) vaccines for COVID-19? Memorial Sloan Kettering Cancer Center (2022).
  22. How does a mRNA vaccine compare to a traditional vaccine? Vumc (2022).
  23. Damase TR., et al. “The limitless future of RNA therapeutics”. Frontiers in Bioengineering and Biotechnology 9 (2021): 628137.
  24. Gupta SK., et al. “The mammalian secreted RNases: mechanisms of action in host defence”. The Innate Immune1 (2013): 86-97.
  25. Hussain A., et al. “mRNA vaccines for COVID-19 and diverse diseases”. Journal of Controlled Release 345 (2022): 314-333.
  26. Understanding mRNA vaccine technologies. The Pharmaceutical Journal (2022).
  27. Mansanguan S., et al. “Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents”. Tropical Medicine and Infectious Disease8 (2022).
  28. Muthukumar A., et al. “In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine”. Circulation6 (2021): 487-498.
  29. Fazlollahi A., et al. “Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series”. Reviews in Medical Virology4 (2022): e2318.
  30. Liu R., et al. “Cardiovascular complications of COVID-19 vaccines”. Frontiers in Cardiovascular Medicine 9 (2022): 840929.
  31. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practice (ACIP). Coronavirus Disease 2019 (COVID-19) Vaccines (2022).
  32. Kuntz J., et al. “Myocarditis and pericarditis are rare following live viral vaccinations in adults”. Vaccine12 (2018): 1524-1527.
  33. García JB., et al. “Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19”. Revista Espanola De Cardiologia9 (2021): 812.
  34. Shimabukuro TT., et al. “Safety monitoring in the vaccine adverse event reporting system (VAERS)”. Vaccine36 (2015): 4398-4405.
  35. Gargano MW., et al. “Oliver Sara E. Morbidity and Mortality Weekly Report. 2021. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States (2021): 977-982.
  36. Hsiao JF., et al. “Speckle tracking echocardiography in acute myocarditis”. The International Journal of Cardiovascular Imaging2 (2013): 275-284.
  37. Wong YK and Tse HF. “Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease”. Frontiers in Cardiovascular Medicine 8 (2021): 713191.
  38. Behers BJ., et al. “Focus: Vaccines: Myocarditis Following COVID-19 Vaccination: A Systematic Review of Case Reports”. The Yale Journal of Biology and Medicine2 (2022).
  39. Oster ME., et al. “Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021”. The Journal of the American Medical Association4 (2022): 331-340.
  40. Patone M., et al. “Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection”. Nature Medicine2 (2022): 410-422.
  41. Boehmer TK., et al. “Association between COVID-19 and myocarditis using hospital-based administrative data-United States”. Morbidity and Mortality Weekly Report 70 (2020): 1228-1232.
  42. Almas T., et al. “Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review”. Biomedicine and Pharmacotherapy112843 (2022): 112843.
  43. Bozkurt B., et al. “Myocarditis with COVID-19 mRNA vaccines”. Circulation6 (2021): 471-484.
  44. Li X., et al. “Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study”. British Medical Journal 373 (2021): n1435.
  45. Wong HL., et al. “Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases”. Lancet10342 (2022): 2191-2199.
  46. Istampoulouoglou I., et al. “Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre”. Global Cardiology Science and Practice 3 (2021).
  47. Diaz GA., et al. “Myocarditis and pericarditis after vaccination for COVID-19”. The Journal of the American Medical Association12 (2021): 1210.
  48. Aye YN., et al. “Acute myocardial infarction and myocarditis following COVID-19 vaccination”. QJM: An International Journal of Medicine (2021).
  49. Sung JG., et al. “Acute myocardial infarction within 24 hours after COVID-19 vaccination”. The American Journal of Cardiology 156 (2021): 129-131.
  50. Greulich S., et al. “Predictors of mortality in patients with biopsy-proven viral myocarditis: 10-year outcome data”. Journal of the American Heart Association16 (2020): e015351.
  51. Heymans S and Cooper LT. “Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms”. Nature Reviews Cardiology2 (2022): 75-77.
  52. Writing Committee Gluckman TJ., et al. “2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: A report of the American college of cardiology solution set oversight committee”. Journal of the American College of Cardiology17 (2022): 1717-1756.
  53. Luk A., et al. “Myocarditis and pericarditis after COVID-19 mRNA vaccination: Practical considerations for care providers”. Canadian Journal of Cardiology10 (2021): 1629-1634.
  54. Sawalha K., et al. “Systematic review of COVID-19 related myocarditis: Insights on management and outcome”. Cardiovascular Revascularization Medicine 23 (2021): 107-113.
  55. Marshall M., et al. “Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination”. Pediatrics3 (2021): e2021052478.
  56. Rabito MJ and Kaye AD. “Complementary and alternative medicine and cardiovascular disease: an evidence-based review”. Evidence-Based Complementary and Alternative Medicine (2013): 672097.
  57. National Center for Complementary and Alternative Medicine (NCCAM). Strategic object 3: increase understanding of ‘real world’ patterns and outcomes of CAM use and its integration into health care and health promotion (2022).
  58. Yeh GY., et al. “Use of complementary therapies in patients with cardiovascular disease”. The American Journal of Cardiology5 (2006): 673-680.
  59. Grant SJ., et al. “The use of complementary and alternative medicine by people with cardiovascular disease: a systematic review”. BMC Public Health1 (2012): 299.
  60. Okoli C., et al. “Use of complementary and alternative medicine among people with cardiovascular diseases in southeast Georgia”. The Journal of the Georgia Public Health Association2 (2019).
  61. Qidwai W., et al. “Role of complementary and alternative medicine in cardiovascular diseases”. Evidence-Based Complementary and Alternative Medicine (2013): 142898.
  62. Miller KL., et al. “Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches”. American Heart Journal3 (2004): 401-411.
  63. Mingorance C., et al. “Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders”. Vascular Health and Risk Management 7 (2011): 169-176.
  64. Liu ZL., et al. “Herbal medicines for viral myocarditis”. Cochrane Database of Systematic Reviews 7 (2010): CD003711.
  65. Ashor AW., et al. “Effect of vitamin C on endothelial function in health and disease: A systematic review and meta-analysis of randomized controlled trials”. Athersclerosis 235 (2014): 9-20.
  66. Berretta M., et al. “Multiple effects of ascorbic acid against chronic diseases: Updated evidence from preclinical and clinical studies”. Antioxidants12 (2020): 1182.
  67. Bahall M. “Complementary and alternative medicine usage among cardiac patients: a descriptive study”. BMC Complementary Medicine and Therapies1 (2015): 100.
  68. Rizos EC., et al. “Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis: A systematic review and meta-analysis”. The Journal of the American Medical Association10 (2012): 1024-1033.
  69. Xu H and Chen KJ. “Herb-drug interaction: an emerging issue of integrative medicine”. Chinese Journal of Integrative Medicine3 (2010): 195-196.
  70. Tachjian A., et al. “Use of herbal products and potential interactions in patients with cardiovascular diseases”. Journal of the American College of Cardiology6 (2010): 515-525.
  71. Pardi N., et al. “mRNA vaccines-a new era in vaccinology”. Nature Reviews Drug Discovery4 (2018): 261-279.

Carsrud NDV, Kerna NA, Holets HM, Chawla S, Flores JV, Ngwu DC, Pruitt KD, Ani CM, Azi CI. "RNA Vaccines and Prevalence of Heart Disorders". EC Cardiology  10.4 (2023): 01-15.